RU98105506A - ORAL USE (+) - O-DEMETHYLTRAMADOL AS ANALGETIC - Google Patents

ORAL USE (+) - O-DEMETHYLTRAMADOL AS ANALGETIC

Info

Publication number
RU98105506A
RU98105506A RU98105506/14A RU98105506A RU98105506A RU 98105506 A RU98105506 A RU 98105506A RU 98105506/14 A RU98105506/14 A RU 98105506/14A RU 98105506 A RU98105506 A RU 98105506A RU 98105506 A RU98105506 A RU 98105506A
Authority
RU
Russia
Prior art keywords
cellulose
demethyltramadol
tablet
pharmaceutically acceptable
use according
Prior art date
Application number
RU98105506/14A
Other languages
Russian (ru)
Inventor
Йозеф Фридрикс Эльмар
Винтер Вернер
Original Assignee
Грюненталь Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Грюненталь Гмбх filed Critical Грюненталь Гмбх
Publication of RU98105506A publication Critical patent/RU98105506A/en

Links

Claims (7)

1. Применение (+)-O-деметилтрамадола в виде свободного основания и/или в виде физиологически приемлемой соли для орального введения при лечении сильных острых и/или хронических болей.1. The use of (+) - O-demethyltramadol in the form of a free base and / or in the form of a physiologically acceptable salt for oral administration in the treatment of severe acute and / or chronic pain. 2. Применение по п. 1, отличающееся тем, что соли (+)-O-деметилтрамадола являются солями органических кислот, в частности С8-С22жирных кислот и ароматических карбоновых кислот.2. The use according to claim 1, characterized in that the salts of (+) - O-demethyltramadol are salts of organic acids, in particular C 8 -C 22 fatty acids and aromatic carboxylic acids. 3. Применение (+)-O-деметилтрамадола по п. 1 или 2 в лекарственном средстве в виде таблетки с замедленным высвобождением активного вещества. 3. The use of (+) - O-demethyltramadol according to claim 1 or 2 in a drug in the form of a tablet with a slow release of the active substance. 4. Применение по п. 3, отличающееся тем, что таблетка представляет собой матричную таблетку. 4. The use of claim 3, wherein the tablet is a matrix tablet. 5. Применение по п. 3, отличающееся тем, что в качестве фармацевтически приемлемого матрицеобразователя используют по меньшей мере один простой и/или сложный эфир целлюлозы, вязкость которого в 2 мас.%-ном водном растворе при 20°С составляет от 3000 до 150000 МПа·с, предпочтительно от 10000 до 150000 МПа·с. 5. The use according to claim 3, characterized in that at least one cellulose ether and / or cellulose ether is used as a pharmaceutically acceptable matrix former, the viscosity of which in a 2 wt.% Aqueous solution at 20 ° C is from 3000 to 150,000 MPa · s, preferably from 10,000 to 150,000 MPa · s. 6. Применение по пп. 3-5, отличающееся тем, что в качестве фармацевтически приемлемого матрицеобразователя используют по меньшей мере одно вещество, выбранное из группы, включающей метилгидроксипропилцеллюлозу, гидроксиэтилцеллюлозу, гидроксипропилцеллюлозу, метилцеллюлозу, этилцеллюлозу и карбоксиметилцеллюлозу. 6. The use of PP. 3-5, characterized in that at least one substance selected from the group consisting of methylhydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose and carboxymethyl cellulose is used as a pharmaceutically acceptable matrix former. 7. Применение по любому из пп. 3-6, отличающееся тем, что содержание замедленно высвобождающегося активного вещества составляет от 10 до 85 мас. %, предпочтительно от 25 до 70 мас.%, а содержание фармацевтически приемлемых матрицеобразователей составляет от 10 до 40 мас.%. 7. The use according to any one of paragraphs. 3-6, characterized in that the content of the slow-release active substance is from 10 to 85 wt. %, preferably from 25 to 70 wt.%, and the content of pharmaceutically acceptable matrixing agents is from 10 to 40 wt.%.
RU98105506/14A 1997-03-25 1998-03-24 ORAL USE (+) - O-DEMETHYLTRAMADOL AS ANALGETIC RU98105506A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19712398.8 1997-03-25

Publications (1)

Publication Number Publication Date
RU98105506A true RU98105506A (en) 2000-01-10

Family

ID=

Similar Documents

Publication Publication Date Title
ES2235152T3 (en) A COMPOUND THAT INCLUDES A TRAMADOL MATERIAL AND A NON-STEROID ANTI-INFLAMMATORY.
RU2203653C2 (en) Using n-propargyl-1-aminoindane r-enantiomer, its salts and compositions comprising thereof
JP2005512995A5 (en)
JP2005515966A5 (en)
AR028504A2 (en) COMBINATION, METHOD FOR IMPROVING THE BODY APPEARANCE OF A MAMMER, PHARMACEUTICAL COMPOSITION, USE OF SUCH COMBINATION FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR PREVENTION, DELAY OF PROGRESS, OR TREATMENT OF METABOLIC DISORDERS, AND COMMERCIAL PACKAGE
ES2530719T3 (en) Oxycodone formulations to be administered once a day
BG66095B1 (en) Pregelatinized starch in a controlled release preparation
MY129234A (en) Oral pharmaceutical forms of administration with a delayed action with tramadol.
ATE424810T1 (en) A DELAYED-RELEASE TABLET CONTAINING A HYDROCOLLOID AND A CELLULOSE ETHER
RU2000123567A (en) PHARMACEUTICAL COMPOSITION, CONTAINING METFORMIN AND FIBRATES IN THE COMBINATION, AND ITS APPLICATION FOR PREPARATION OF MEDICINES, INTENDED TO REDUCE HYPERGLYCEMIA
CL2004001182A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A MICROPARTICLE OF SUSTAINED RELEASE THAT CONTAINS A DERIVATIVE OF 1,2 BENZAZOL; MICROPARTICLE PREPARATION PROCEDURE; USEFUL AS BRONCODILATADOR, ANTIPSICOTICOS AND IN OTHER PROBLEMS OF THE S
EA200000246A1 (en) QUICKLY DISINTEGRATING METAL CELLULOSE TABLETS
JP2002531505A5 (en)
CO5060477A1 (en) DOSAGE FORM OF NEFAZODONA
EA200001201A2 (en) Matrix tablet for prolonged release of trimetazidine
RU99120189A (en) DRUGS FOR TREATMENT OF A METABOLIC SYNDROME CONTAINING A HUMAN GROWTH HORMONE IN COMBINATION WITH A CORTZOL SYNTHESIS INHIBITOR
SK282506B6 (en) Pill containing paracetamol and domperidon
JP2001510795A5 (en)
NZ514129A (en) Tolperison-containing, pharmaceutical preparation for oral administration
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
RU2002105375A (en) APPLICATION OF GABAB RECEPTOR AGONISTS AND THEIR PHARMACEUTICALLY ACCEPTABLE DERIVATIVES FOR SUPPORTING THERAPY OF NICOTINE-DEPENDENT PATIENTS
RU2005105302A (en) BICYPHADINE COMPOSITION
RU2002130719A (en) ACTIVATIVE COMPOSITION
RU98105506A (en) ORAL USE (+) - O-DEMETHYLTRAMADOL AS ANALGETIC
RU2005135647A (en) COMBINATIONS INCLUDING PAROXETIN AND {1- (R) - (3.5-BIS-TRIFTOR-2-METHYLPHENYL) Ethylmethylamide} -2- (S) - (4-FLUOR-2-METHYLPHENYL) PIPERAZINE-1-CARBETONE DEPRESSIONS AND / OR ALARMS